{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:07:57Z","timestamp":1788743277194,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T19:46:47Z","timestamp":1777751207000},"page":"200-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Testicular Germ Cell Tumours: Personalised Treatment Approaches Are on Their Way"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-3664","authenticated-orcid":false,"given":"Axel","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.04.015_b0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.eururo.2026.03.018","article-title":"Diagnostic accuracy of circulating tumor DNA to predict retroperitoneal histology in patients treated with retroperitoneal lymph node dissection for testicular germ tumor","volume":"90","author":"Thakker","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.015_b0010","unstructured":"Heidenreich A, Berney DM, Boormans JL, et al. EAU guidelines on Testicular Cancer. Accessed March 28, 2026. Uroweb.org\/guidelines\/testicular-cancer."},{"key":"10.1016\/j.eururo.2026.04.015_b0015","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1200\/JCO.21.00637","article-title":"Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort","volume":"39","author":"Hellesnes","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.015_b0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/OP-25-00252","article-title":"Optimal management of Stage II seminoma: preventing harm while preserving cure","volume":"22","author":"Conduit","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.eururo.2026.04.015_b0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2025.08.013","article-title":"Role of retroperitoneal lymph node dissection in clinical stage IIA\/B seminoma: recommendations from the European Association of Urology guidelines panel on testicular cancer","volume":"88","author":"Heidenreich","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.015_b0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2025.03.002","article-title":"Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors","volume":"36","author":"Matulewicz","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.015_b0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euo.2023.10.021","article-title":"Evaluation of a miRNA-371a-3p assay for predicting final histopathology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy for stage IIA\/B seminoma or nonseminoma","volume":"7","author":"Seelemeyer","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.015_b0040","first-page":"S1","article-title":"A0321: evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy (nsRPLND) for stage IIA\/B seminomas and non-seminomas (NSGCT)","volume":"89","author":"Heidenreich","year":"2026","journal-title":"European Urology"},{"key":"10.1016\/j.eururo.2026.04.015_b0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00345-025-05571-y","article-title":"Diagnostic efficacy of serum microRNAs in predicting pathology of retroperitoneal lymph node dissection in patients with testicular germ cell tumors: a systematic review and meta-analysis","volume":"43","author":"Kardoust Parizi","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.015_b0050","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00330-019-06495-z","article-title":"Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection","volume":"30","author":"Baessler","year":"2020","journal-title":"Eur Radiol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:26:55Z","timestamp":1788740815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826021172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0302283826021172"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.015","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Testicular Germ Cell Tumours: Personalised Treatment Approaches Are on Their Way","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}